{"gene":"TM6SF2","run_date":"2026-06-10T10:51:55","timeline":{"discoveries":[{"year":2014,"finding":"TM6SF2 is localized in the endoplasmic reticulum and ER-Golgi intermediate compartment of human liver cells, and siRNA knockdown reduces secretion of triglyceride-rich lipoproteins while increasing intracellular triglyceride content and lipid droplet content; overexpression reduces hepatocyte steatosis.","method":"Confocal microscopy subcellular localization, siRNA knockdown, overexpression in Huh7 and HepG2 cells with lipid/TG secretion assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal loss-of-function and gain-of-function experiments with multiple orthogonal methods (confocal localization, siRNA, overexpression, TG secretion assay) in human hepatoma cells","pmids":["24927523"],"is_preprint":false},{"year":2014,"finding":"AAV-mediated shRNA knockdown of Tm6sf2 in mice increased liver triglyceride content threefold and decreased VLDL secretion by 50%, establishing TM6SF2 as required for normal VLDL secretion in vivo; the E167K variant produces ~50% less protein when expressed in cultured hepatocytes.","method":"AAV-shRNA knockdown in mice, VLDL secretion assays, recombinant protein expression in hepatocytes","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo mouse knockdown with quantitative VLDL secretion readout replicated across multiple independent lines of evidence","pmids":["24531328"],"is_preprint":false},{"year":2016,"finding":"Genetic inactivation of Tm6sf2 in mice causes hepatic steatosis, hypocholesterolemia, and reduced VLDL-TG secretion (3-fold decrease in rate) without reduction in hepatic apoB secretion; TM6SF2 localizes to ER and Golgi; excess neutral lipids accumulate in lipid droplets distinct from TM6SF2 localization, indicating TM6SF2 is required to mobilize neutral lipids for VLDL assembly but not for apoB-containing lipoprotein secretion per se.","method":"Germline Tm6sf2 knockout mice, immunocytochemistry, cell fractionation, VLDL-TG secretion rate measurement, dietary lipid absorption assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — full knockout mouse model with multiple orthogonal quantitative methods separating TG secretion from apoB secretion","pmids":["27013658"],"is_preprint":false},{"year":2021,"finding":"Liver-specific Tm6sf2 knockout mice exhibit spontaneous hepatic steatosis with reduced VLDL-TG secretion, small underlipidated VLDL particles, and unchanged or increased apolipoprotein B; AAV8-mediated rescue with either wild-type or E167K-mutant Tm6sf2 reduced hepatic steatosis and improved VLDL secretion; on fibrogenic diets, Tm6sf2 LKO mice show increased steatosis, fibrosis, and accelerated HCC.","method":"Liver-specific conditional knockout mice (two independent lines), AAV8 rescue, targeted lipidomics, in vivo VLDL secretion, dietary challenge models, HCC induction models","journal":"Hepatology (Baltimore, Md.)","confidence":"High","confidence_rationale":"Tier 2 / Strong — two independent knockout lines, AAV rescue, lipidomics, multiple disease models in a single rigorous study","pmids":["33638902"],"is_preprint":false},{"year":2021,"finding":"TM6SF2 resides predominantly in smooth endoplasmic reticulum and ER-Golgi intermediate compartments (not Golgi). In Tm6sf2-knockout rats, VLDL lipid content (TG and cholesterol) from perfused livers was reduced by ~53–62%. Immunoprecipitation identified apolipoprotein B-48 and ACSL5 (acyl-CoA synthetase long chain family member 5) as TM6SF2-interacting proteins, placing TM6SF2 function at the smooth ER for bulk lipidation of apoB-containing lipoproteins.","method":"Gene-edited Tm6sf2-knockout rats, cell fractionation, perfused liver VLDL lipid quantification by mass spectrometry, co-immunoprecipitation from liver and enterocytes","journal":"Cellular and molecular gastroenterology and hepatology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — orthogonal methods including cell fractionation, perfused liver VLDL quantification, and co-IP identifying specific binding partners","pmids":["34923175"],"is_preprint":false},{"year":2020,"finding":"TM6SF2 forms a complex with ERLIN1, ERLIN2, and APOB. ERLINs and TM6SF2 mutually bind and stabilize each other. TM6SF2 binds and stabilizes APOB via two luminal loops; the E167K mutation reduces TM6SF2 protein expression, destabilizing APOB and leading to hepatic lipid accumulation and reduced serum lipid levels. Knockout of Tm6sf2 or knockdown of Erlins in mice decreases hepatic APOB protein level.","method":"Tandem affinity purification combined with mass spectrometry, co-IP, mutagenesis (luminal loop mapping), mouse Tm6sf2 KO and Erlin knockdown with hepatic lipid and APOB measurements","journal":"PLoS genetics","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — TAP-MS for complex identification, co-IP validation, domain mutagenesis, and in vivo mouse KO confirmation in a single study","pmids":["32776921"],"is_preprint":false},{"year":2017,"finding":"Hepatic overexpression of Tm6sf2 in mice (via AAV) reduces plasma lipid levels and VLDL-TG secretion and increases hepatosteatosis, mirroring loss-of-function phenotype. In cultured human hepatocytes, TM6SF2 overexpression reduces apoB secretion and causes its accumulation in the ER, suggesting impaired ER-to-Golgi trafficking of pre-VLDL particles. Both E167K (rs58542926) and L156P (rs187429064) variants reduce TM6SF2 protein by increasing protein turnover rate.","method":"AAV-mediated hepatic overexpression in mice, cultured human hepatocyte apoB secretion assay, protein turnover experiments comparing variant vs. wild-type TM6SF2","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo overexpression mouse model, in vitro human hepatocyte mechanistic assay, and biochemical protein stability analysis in one study","pmids":["28449094"],"is_preprint":false},{"year":2017,"finding":"TM6SF2 knockdown in HuH7 cells results in intracellular accumulation of TAGs and cholesterol esters with depletion of polyunsaturated fatty acid species (especially arachidonic acid) in phosphatidylcholines, increased lipid synthesis and turnover, secretion of smaller lipoprotein-like particles, increased lysosome/endosome structures, and reduced mitochondrial palmitate oxidation capacity.","method":"Stable siRNA knockdown in HuH7 cells, lipidomics (lipid class and species composition), mitochondrial fatty acid oxidation assay, electron microscopy","journal":"Biochimica et biophysica acta. Molecular and cell biology of lipids","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods in a single lab with stable knockdown and quantitative lipid/functional readouts","pmids":["28434889"],"is_preprint":false},{"year":2017,"finding":"In human liver biopsies and TM6SF2 knockdown HuH-7 cells, TM6SF2 E167K variant carriers show decreased polyunsaturated fatty acid (PUFA) incorporation into triglycerides and phosphatidylcholines (PC), with PC deficiency and increased intrahepatic TG, demonstrating that TM6SF2 is required for hepatic lipid synthesis from PUFAs.","method":"Liver biopsies with genotyping and lipidomics, siRNA knockdown in HuH-7 cells with fatty acid incorporation assays, gene co-expression analysis","journal":"Journal of hepatology","confidence":"High","confidence_rationale":"Tier 2 / Strong — human liver biopsy lipidomics combined with cell-based PUFA incorporation assays, replicated across in vivo and in vitro contexts","pmids":["28235613"],"is_preprint":false},{"year":2021,"finding":"TM6SF2 silencing in HepG2 cells (via CRISPR/Cas9) alters lipid composition, induces accumulation of microvesicular lipid droplets, strongly affects ER and mitochondrial ultrastructure, increases ER and oxidative stress, increases mitochondrial number (imbalanced mitochondrial dynamics), and impairs mitochondrial activity with shift toward anaerobic glycolysis. Re-overexpression of TM6SF2 reverses these metabolic and tumorigenic features.","method":"CRISPR/Cas9 knockout in HepG2 cells, electron microscopy (ultrastructure), mitochondrial function assays, metabolic reprogramming assays, rescue overexpression","journal":"Cellular and molecular gastroenterology and hepatology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — CRISPR KO with rescue, multiple orthogonal functional readouts in a single lab","pmids":["34823063"],"is_preprint":false},{"year":2018,"finding":"TM6SF2 knockdown in hepatocytes reduces HCV infectious viral particle secretion and RNA levels without affecting HCV genome replication, translation, or assembly; TM6SF2 overexpression increases secretion of infectious lipoviroparticles in lower-density fractions. HCV infection upregulates TM6SF2 expression via SREBF2, and TM6SF2 is required for maturation, lipidation, and secretion of HCV lipoviroparticles.","method":"siRNA knockdown and overexpression in HCV-infected hepatocytes, iodixanol gradient density fractionation of LVPs, viral RNA/protein quantification, liver biopsies from HCV patients and humanized mice","journal":"Gastroenterology","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal KD/OE experiments with quantitative viral secretion readout, corroborated by humanized mouse and human biopsy data","pmids":["30144428"],"is_preprint":false},{"year":2024,"finding":"TM6SF2 knockdown in human hepatocytes reduces secretion of infectious HBV subviral particles, HCV virions, and HDV virions; carriers of the TM6SF2 rs58542926 CT/TT polymorphism have lower HBV subviral particle concentrations in blood, demonstrating TM6SF2 as a host factor required for secretion of all three hepatitis viruses via the ER-Golgi pathway.","method":"siRNA knockdown in virus cell culture models for HBV, HCV, HDV; clinical cohort correlation of TM6SF2 polymorphism with HBV subviral particle levels","journal":"The Journal of infectious diseases","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell-based KD with multiple virus systems, supported by clinical cohort data, single lab","pmids":["38408366"],"is_preprint":false},{"year":2021,"finding":"TM6SF2 interacts with IRE1α (inositol-requiring enzyme 1α), a primary ER stress sensor; male E167K knock-in mice exhibit impaired IRE1α signaling in the liver and glucose intolerance, while female KI mice do not, indicating sex-specific TM6SF2-IRE1α interaction effects on glucose metabolism.","method":"E167K knock-in mouse model, glucose tolerance testing, co-immunoprecipitation of TM6SF2 with IRE1α, hepatic IRE1α signaling assays","journal":"iScience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KI mouse model with co-IP interaction and functional metabolic readout, single lab","pmids":["34746691"],"is_preprint":false},{"year":2025,"finding":"Intestinal epithelial cell-specific Tm6sf2 knockout mice develop MASH; mechanistically, Tm6sf2-deficient intestinal cells secrete more free fatty acids by interacting with fatty acid-binding protein 5 (FABP5), causing intestinal barrier dysfunction, microbial dysbiosis, and elevation of lysophosphatidic acid (LPA). LPA translocates from gut to liver contributing to hepatic lipid accumulation and inflammation. Pharmacological inhibition of the LPA receptor suppresses MASH.","method":"Intestinal epithelial-specific Tm6sf2 KO mice, germ-free fecal transplant experiments, co-housing with wild-type mice, LPA measurement, LPA receptor inhibitor treatment, co-immunoprecipitation with FABP5","journal":"Nature metabolism","confidence":"High","confidence_rationale":"Tier 2 / Strong — intestine-specific KO with germ-free transplant and co-housing mechanistic controls, molecular interaction identified, pharmacological rescue, multiple orthogonal methods","pmids":["39779889"],"is_preprint":false},{"year":2025,"finding":"Hepatic TM6SF2 directly binds IKKβ and inhibits NF-κB signaling, reducing IL-6 secretion and thereby maintaining cytotoxic CD8+ T cell activity; hepatocyte-specific Tm6sf2 knockout reduces IFN-γ+ CD8+ T cells in tumors and promotes MASLD-HCC, while IL-6 neutralization abolishes the tumor-promoting effect of Tm6sf2 knockout.","method":"Hepatocyte-specific Tm6sf2 KO mice, orthotopic MASLD-HCC models, co-immunoprecipitation of TM6SF2 with IKKβ, NF-κB signaling assays, CD8+ T cell depletion, IL-6 neutralization, adenoviral TM6SF2 overexpression","journal":"Gut","confidence":"High","confidence_rationale":"Tier 2 / Strong — hepatocyte-specific KO with co-IP molecular interaction, NF-κB pathway assays, immune cell depletion, cytokine neutralization, and viral rescue across multiple models","pmids":["39667906"],"is_preprint":false},{"year":2022,"finding":"TM6SF2 deficiency in macrophages (myeloid-specific KO on ApoE-/- background) inhibits atherosclerosis and decreases foam cell formation without changing plasma lipids. Silencing TM6SF2 in THP-1 macrophages reduces inflammatory responses, ER stress, and cholesterol uptake; TM6SF2 is upregulated by oxLDL in macrophages; overexpression shows opposite effects.","method":"Myeloid-specific Tm6sf2 KO mice on ApoE-/- background, Western diet atherosclerosis model, RNA-seq of BMDMs, siRNA knockdown and overexpression in THP-1 macrophages with cholesterol uptake and ER stress assays","journal":"Cells","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell-type-specific KO mouse model with reciprocal KD/OE in macrophages, multiple functional readouts, single lab","pmids":["36139452"],"is_preprint":false},{"year":2023,"finding":"TM6SF2 reduces lipid accumulation in vascular smooth muscle cells (VSMCs) exposed to oxLDL by downregulating expression of the scavenger receptors LOX-1 and CD36.","method":"siRNA knockdown and overexpression of TM6SF2 in HAVSMCs, lipid accumulation assay, LOX-1 and CD36 expression measurement","journal":"Experimental cell research","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, single cell type, KD/OE with gene expression readout but limited mechanistic depth","pmids":["37271250"],"is_preprint":false},{"year":2024,"finding":"The TM6SF2 E167K variant increases interaction between TM6SF2 and PNPLA3, impairing PNPLA3-mediated transfer of polyunsaturated fatty acids (PUFAs) from TG to PC; this results in decreased polyunsaturated PC and increased polyunsaturated TG in liver. Dietary supplementation of PC containing C18:3 attenuates E167K-induced hepatic steatosis in HFD-fed mice.","method":"Tm6sf2 E167K knock-in mice on HFD, hepatic lipidomics, TLC for newly synthesized TG/PC, co-immunoprecipitation of TM6SF2 with PNPLA3 (comparing WT vs. E167K), dietary PC C18:3 supplementation","journal":"Clinical and molecular hepatology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KI mouse model with co-IP interaction mapping, lipidomics, and dietary rescue, single lab","pmids":["39054606"],"is_preprint":false},{"year":2014,"finding":"Computational sequence analysis identified a novel conserved domain (EXPERA domain) shared between TM6SF2, MAC30/TMEM97, and EBP (D8/D7 sterol isomerase) families, predicting catalytic activity as a sterol isomerase for TM6SF2 based on evolutionary conservation of predicted active-site residues.","method":"Computational protein sequence analysis, evolutionary conservation analysis, domain prediction","journal":"Frontiers in genetics","confidence":"Low","confidence_rationale":"Tier 4 / Weak — computational prediction only, no experimental validation of enzymatic activity in this study","pmids":["25566323"],"is_preprint":false},{"year":2019,"finding":"In human hepatic 3D spheroids from primary hepatocytes, the TM6SF2 E167K variant induces increased hepatocyte fat content by reducing APOB particle secretion, confirmed across five donors with inter-donor variability reflected in the model.","method":"3D spheroid model from primary human hepatocytes with TM6SF2 E167K variant carriers vs. wild-type, APOB secretion measurement, lipid content assay","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — primary human hepatocyte 3D model with multiple donors, functional APOB secretion readout, single lab","pmids":["31406127"],"is_preprint":false},{"year":2022,"finding":"TM6SF2 deficiency (knockdown) in hepatocytes enhances fatty acid uptake and synthesis and impairs fatty acid oxidation, leading to intracellular lipid deposition. Treatment with the acetyl-CoA carboxylase inhibitor MK-4074 reverses NAFLD phenotypes caused by TM6SF2 deficiency, placing TM6SF2 upstream of de novo lipogenesis regulation.","method":"siRNA knockdown and overexpression in hepatocytes, RNA-seq, in vivo NAFLD mouse model, MK-4074 pharmacological rescue","journal":"World journal of gastroenterology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell KD/OE with gene expression analysis and pharmacological rescue, single lab","pmids":["35978872"],"is_preprint":false},{"year":2024,"finding":"The protective effect of the ERLIN1 p.Ile291Val variant against MASLD is not apparent in individuals carrying the TM6SF2 p.Glu167Lys variant, suggesting functional epistasis: ERLIN1 p.Ile291Val may act as a gain-of-function variant that enhances TM6SF2 function, consistent with the known ERLIN1-TM6SF2-APOB complex.","method":"Genome-first approach in UK Biobank, Penn Medicine Biobank, and All of Us cohorts; predicted loss-of-function ERLIN1 variant analysis showing opposite lipid effects; epistasis analysis with TM6SF2 E167K","journal":"Med (New York, N.Y.)","confidence":"Low","confidence_rationale":"Tier 3 / Weak — human genetic epistasis inference from biobank data without direct biochemical validation of ERLIN1-TM6SF2 functional interaction","pmids":["38776916"],"is_preprint":false}],"current_model":"TM6SF2 is a polytopic ER-resident membrane protein (with EXPERA domain) that localizes to the smooth ER and ER-Golgi intermediate compartment where it forms a complex with ERLIN1/2 and stabilizes APOB, promotes bulk lipidation of nascent apoB-containing VLDL particles (required for TG loading but dispensable for apoB secretion per se), facilitates PUFA incorporation into phosphatidylcholines, enables secretion of hepatitis B/C/D virions via the ER-Golgi pathway, suppresses NF-κB/IKKβ-IL-6 signaling to maintain hepatic antitumor CD8+ T cell immunity, and in intestinal cells interacts with FABP5 to regulate fatty acid secretion and gut-liver LPA signaling; the disease-associated E167K variant reduces protein stability/expression, impairs VLDL lipidation and APOB stabilization, increases interaction with PNPLA3 to block PUFA transfer from TG to PC, and activates ER stress—collectively causing hepatic steatosis, fibrosis, and increased HCC risk."},"narrative":{"mechanistic_narrative":"TM6SF2 is an endoplasmic reticulum and ER-Golgi intermediate compartment membrane protein that governs hepatic lipid mobilization for the assembly and secretion of triglyceride-rich VLDL particles [PMID:24927523, PMID:27013658]. Loss of TM6SF2 in cells, mice, and rats reduces VLDL-TG secretion and causes intracellular triglyceride and lipid-droplet accumulation, yet leaves apoB secretion intact, establishing that TM6SF2 acts to lipidate nascent apoB-containing particles rather than to drive their secretion per se [PMID:24531328, PMID:27013658, PMID:33638902]. Mechanistically, TM6SF2 localizes to the smooth ER where it binds apolipoprotein B-48 and ACSL5 to support bulk lipidation [PMID:34923175], and it assembles into a complex with ERLIN1/ERLIN2 in which TM6SF2 and the ERLINs mutually stabilize one another and TM6SF2 binds and stabilizes APOB through two luminal loops [PMID:32776921]. TM6SF2 also directs polyunsaturated fatty acid incorporation into phosphatidylcholines and triglycerides, a function required for normal hepatic lipid synthesis [PMID:28434889, PMID:28235613]. Beyond lipoprotein biology, TM6SF2 is a host factor required for ER-Golgi-dependent secretion of hepatitis B, C, and D viral particles [PMID:30144428, PMID:38408366], and in hepatocytes it binds IKKβ to suppress NF-κB/IL-6 signaling and sustain antitumor CD8+ T cell immunity, restraining MASLD-driven HCC [PMID:39667906]. In intestinal epithelium TM6SF2 interacts with FABP5 to limit free fatty acid secretion, and its loss drives a gut-liver axis of dysbiosis and lysophosphatidic acid signaling that promotes MASH [PMID:39779889]. The common E167K variant destabilizes TM6SF2 by accelerating its turnover, reducing protein levels, destabilizing APOB, and impairing VLDL lipidation [PMID:32776921, PMID:28449094, PMID:31406127]; E167K additionally increases TM6SF2 interaction with PNPLA3 to block PUFA transfer from triglyceride to phosphatidylcholine, collectively causing steatosis, fibrosis, and elevated HCC risk [PMID:33638902, PMID:39054606].","teleology":[{"year":2014,"claim":"Established the core question of TM6SF2 function by showing it is an ER/ERGIC protein whose loss blocks triglyceride-rich lipoprotein secretion and causes hepatocellular lipid retention.","evidence":"Confocal localization with reciprocal siRNA knockdown and overexpression in Huh7/HepG2 cells; AAV-shRNA knockdown in mice with VLDL secretion assays","pmids":["24927523","24531328"],"confidence":"High","gaps":["Did not resolve whether the defect was in lipid loading or in particle secretion machinery","Molecular partners and biochemical activity unidentified"]},{"year":2016,"claim":"Resolved the step at which TM6SF2 acts by showing germline knockout reduces VLDL-TG secretion without reducing apoB secretion, separating lipidation from lipoprotein secretion.","evidence":"Germline Tm6sf2 knockout mice with VLDL-TG secretion rate measurement, fractionation, and lipid absorption assays","pmids":["27013658"],"confidence":"High","gaps":["No binding partners or enzymatic activity defined","Mechanism of neutral lipid mobilization to nascent particles unknown"]},{"year":2017,"claim":"Defined the lipid-species consequences of TM6SF2 loss, linking it to PUFA incorporation into phosphatidylcholines and triglycerides and to broader metabolic remodeling.","evidence":"Stable siRNA knockdown in HuH7 cells with lipidomics, mitochondrial oxidation and EM; human liver biopsy lipidomics with PUFA incorporation assays; AAV overexpression in mice and hepatocyte protein turnover assays","pmids":["28434889","28235613","28449094"],"confidence":"High","gaps":["Direct enzyme catalyzing PUFA transfer not identified at this stage","Mechanistic basis for variant protein instability not fully resolved"]},{"year":2020,"claim":"Identified the molecular complex underlying TM6SF2 function by showing it binds and is mutually stabilized by ERLIN1/2 and stabilizes APOB via luminal loops, explaining how E167K causes APOB destabilization.","evidence":"Tandem affinity purification-mass spectrometry, co-IP, luminal-loop mutagenesis, and mouse KO/Erlin knockdown with hepatic APOB measurement","pmids":["32776921"],"confidence":"High","gaps":["Stoichiometry and structure of the TM6SF2-ERLIN-APOB complex not determined","How the complex couples to lipid loading mechanistically unresolved"]},{"year":2021,"claim":"Mapped TM6SF2 to the smooth ER and identified apoB-48 and ACSL5 as interacting partners, and confirmed in liver-specific KO that TM6SF2 produces underlipidated VLDL and drives steatosis, fibrosis, and HCC.","evidence":"Tm6sf2-knockout rats with perfused-liver VLDL lipid quantification and co-IP; liver-specific conditional KO mice with AAV8 rescue, lipidomics, and disease models; CRISPR KO in HepG2 with ultrastructure and mitochondrial assays","pmids":["34923175","33638902","34823063"],"confidence":"High","gaps":["Functional role of ACSL5 interaction in lipidation not dissected","Causal chain from steatosis to fibrosis/HCC not fully mechanistic"]},{"year":2018,"claim":"Extended TM6SF2 function to viral pathogenesis by showing it is required for maturation, lipidation, and secretion of HCV lipoviroparticles without affecting genome replication.","evidence":"siRNA knockdown/overexpression in HCV-infected hepatocytes with density gradient fractionation, plus humanized mouse and patient biopsy data","pmids":["30144428"],"confidence":"High","gaps":["Whether HCV co-opts the same ERLIN/APOB machinery untested","Direct interaction with viral components not shown"]},{"year":2024,"claim":"Generalized TM6SF2 as a pan-hepatitis host secretion factor for HBV, HCV, and HDV virions via the ER-Golgi pathway, with the E167K-associated genotype lowering circulating HBV subviral particles.","evidence":"siRNA knockdown across HBV/HCV/HDV cell culture models with clinical cohort polymorphism correlation","pmids":["38408366"],"confidence":"Medium","gaps":["Single-lab cell-based knockdown without reciprocal validation across systems","Mechanism of shared secretion route not biochemically defined"]},{"year":2021,"claim":"Connected TM6SF2 to ER stress sensing by demonstrating interaction with IRE1α and sex-specific effects of E167K on hepatic IRE1α signaling and glucose tolerance.","evidence":"E167K knock-in mice with glucose tolerance testing, co-IP of TM6SF2 with IRE1α, and hepatic IRE1α signaling assays","pmids":["34746691"],"confidence":"Medium","gaps":["Basis of sex-specificity unexplained","Single Co-IP for the IRE1α interaction without reciprocal/structural validation"]},{"year":2022,"claim":"Revealed cell-type-specific roles of TM6SF2 beyond hepatocytes, in macrophage foam-cell formation, atherosclerosis, ER stress, and de novo lipogenesis regulation.","evidence":"Myeloid-specific Tm6sf2 KO on ApoE-/- background with atherosclerosis model and macrophage KD/OE; hepatocyte KD/OE with RNA-seq and ACC inhibitor MK-4074 rescue","pmids":["36139452","35978872"],"confidence":"Medium","gaps":["Molecular mechanism in macrophages not resolved to direct partners","Single-lab studies with gene-expression readouts"]},{"year":2024,"claim":"Defined a molecular mechanism for the E167K variant beyond protein instability by showing it increases TM6SF2-PNPLA3 interaction to block PUFA transfer from TG to PC, with dietary PC rescue.","evidence":"Tm6sf2 E167K knock-in mice on HFD with hepatic lipidomics, TLC, co-IP comparing WT vs E167K, and dietary PC C18:3 supplementation","pmids":["39054606"],"confidence":"Medium","gaps":["Direct enzymatic role of TM6SF2 in PUFA transfer versus modulation of PNPLA3 not separated","Single-lab co-IP interaction mapping"]},{"year":2025,"claim":"Identified non-cell-autonomous gut-liver and immune mechanisms: intestinal TM6SF2 limits FFA secretion via FABP5 to control an LPA gut-liver axis, while hepatic TM6SF2 binds IKKβ to suppress NF-κB/IL-6 and preserve antitumor CD8+ T cell immunity.","evidence":"Intestinal-specific KO with germ-free transplant, co-housing, LPA receptor inhibitor, and FABP5 co-IP; hepatocyte-specific KO with orthotopic HCC models, IKKβ co-IP, CD8+ T cell depletion, IL-6 neutralization, and viral rescue","pmids":["39779889","39667906"],"confidence":"High","gaps":["How a lipidation protein engages IKKβ and FABP5 mechanistically unresolved","Interplay between metabolic and immune functions of TM6SF2 not integrated"]},{"year":null,"claim":"The intrinsic biochemical activity of TM6SF2 — whether it possesses the predicted EXPERA/sterol-isomerase catalytic function or acts purely as a scaffold for lipid loading — remains undefined.","evidence":"","pmids":[],"confidence":"Low","gaps":["EXPERA-domain catalytic activity predicted computationally but never experimentally demonstrated","No structure of TM6SF2 or its complexes","Mechanistic coupling of partner binding to bulk lipidation unresolved"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[7,8,17]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[4,5]}],"localization":[{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[0,2,4]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[2,3,7,8]},{"term_id":"R-HSA-5653656","term_label":"Vesicle-mediated transport","supporting_discovery_ids":[0,1,10]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[3,13,14]}],"complexes":["TM6SF2-ERLIN1/ERLIN2-APOB complex"],"partners":["APOB","ERLIN1","ERLIN2","ACSL5","IRE1A","PNPLA3","FABP5","IKBKB"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9BZW4","full_name":"Transmembrane 6 superfamily member 2","aliases":[],"length_aa":377,"mass_kda":42.6,"function":"Regulator of liver fat metabolism influencing triglyceride secretion and hepatic lipid droplet content (PubMed:24531328, PubMed:24927523). May function as sterol isomerase (PubMed:25566323)","subcellular_location":"Endoplasmic reticulum membrane; Endoplasmic reticulum-Golgi intermediate compartment membrane","url":"https://www.uniprot.org/uniprotkb/Q9BZW4/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TM6SF2","classification":"Not Classified","n_dependent_lines":17,"n_total_lines":1208,"dependency_fraction":0.014072847682119206},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/TM6SF2","total_profiled":1310},"omim":[{"mim_id":"606563","title":"TRANSMEMBRANE 6 SUPERFAMILY, MEMBER 2; TM6SF2","url":"https://www.omim.org/entry/606563"},{"mim_id":"606562","title":"TRANSMEMBRANE 6 SUPERFAMILY, MEMBER 1; TM6SF1","url":"https://www.omim.org/entry/606562"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Group enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"intestine","ntpm":71.1},{"tissue":"liver","ntpm":32.0}],"url":"https://www.proteinatlas.org/search/TM6SF2"},"hgnc":{"alias_symbol":["Lpr4"],"prev_symbol":[]},"alphafold":{"accession":"Q9BZW4","domains":[{"cath_id":"-","chopping":"9-192","consensus_level":"high","plddt":92.3398,"start":9,"end":192},{"cath_id":"-","chopping":"202-362","consensus_level":"high","plddt":95.7191,"start":202,"end":362}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9BZW4","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9BZW4-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9BZW4-F1-predicted_aligned_error_v6.png","plddt_mean":91.0},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TM6SF2","jax_strain_url":"https://www.jax.org/strain/search?query=TM6SF2"},"sequence":{"accession":"Q9BZW4","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9BZW4.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9BZW4/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9BZW4"}},"corpus_meta":[{"pmid":"24531328","id":"PMC_24531328","title":"Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease.","date":"2014","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24531328","citation_count":973,"is_preprint":false},{"pmid":"24978903","id":"PMC_24978903","title":"TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease.","date":"2014","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/24978903","citation_count":494,"is_preprint":false},{"pmid":"24927523","id":"PMC_24927523","title":"TM6SF2 is a regulator of liver fat metabolism influencing triglyceride secretion and hepatic lipid droplet content.","date":"2014","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/24927523","citation_count":287,"is_preprint":false},{"pmid":"24633158","id":"PMC_24633158","title":"Systematic evaluation of coding variation identifies a candidate causal variant in TM6SF2 influencing total cholesterol and myocardial infarction risk.","date":"2014","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24633158","citation_count":239,"is_preprint":false},{"pmid":"32190914","id":"PMC_32190914","title":"Combined Effect of PNPLA3, TM6SF2, and HSD17B13 Variants on Risk of Cirrhosis and Hepatocellular Carcinoma in the General Population.","date":"2020","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/32190914","citation_count":190,"is_preprint":false},{"pmid":"27013658","id":"PMC_27013658","title":"Inactivation of Tm6sf2, a Gene Defective in Fatty Liver Disease, Impairs Lipidation but Not Secretion of Very Low Density Lipoproteins.","date":"2016","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/27013658","citation_count":175,"is_preprint":false},{"pmid":"26457389","id":"PMC_26457389","title":"Role of TM6SF2 rs58542926 in the pathogenesis of nonalcoholic pediatric fatty liver disease: A multiethnic study.","date":"2015","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/26457389","citation_count":110,"is_preprint":false},{"pmid":"28235613","id":"PMC_28235613","title":"Impaired hepatic lipid synthesis from polyunsaturated fatty acids in TM6SF2 E167K variant carriers with NAFLD.","date":"2017","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/28235613","citation_count":106,"is_preprint":false},{"pmid":"34532996","id":"PMC_34532996","title":"TM6SF2: A Novel Genetic Player in Nonalcoholic Fatty Liver and Cardiovascular Disease.","date":"2021","source":"Hepatology communications","url":"https://pubmed.ncbi.nlm.nih.gov/34532996","citation_count":103,"is_preprint":false},{"pmid":"25457209","id":"PMC_25457209","title":"Circulating triacylglycerol signatures and insulin sensitivity in NAFLD associated with the E167K variant in TM6SF2.","date":"2014","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/25457209","citation_count":96,"is_preprint":false},{"pmid":"26822232","id":"PMC_26822232","title":"Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes.","date":"2016","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/26822232","citation_count":90,"is_preprint":false},{"pmid":"31406127","id":"PMC_31406127","title":"The TM6SF2 E167K genetic variant induces lipid biosynthesis and reduces apolipoprotein B secretion in human hepatic 3D spheroids.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31406127","citation_count":90,"is_preprint":false},{"pmid":"34823063","id":"PMC_34823063","title":"TM6SF2/PNPLA3/MBOAT7 Loss-of-Function Genetic Variants Impact on NAFLD Development and Progression Both in Patients and in In Vitro Models.","date":"2021","source":"Cellular and molecular gastroenterology and hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/34823063","citation_count":89,"is_preprint":false},{"pmid":"26272871","id":"PMC_26272871","title":"Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: Results from the WELCOME trial.","date":"2015","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/26272871","citation_count":88,"is_preprint":false},{"pmid":"33638902","id":"PMC_33638902","title":"Liver-Specific Deletion of Mouse Tm6sf2 Promotes Steatosis, Fibrosis, and Hepatocellular Cancer.","date":"2021","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/33638902","citation_count":87,"is_preprint":false},{"pmid":"25893821","id":"PMC_25893821","title":"TM6SF2 Glu167Lys polymorphism is associated with low levels of LDL-cholesterol and increased liver injury in obese children.","date":"2015","source":"Pediatric obesity","url":"https://pubmed.ncbi.nlm.nih.gov/25893821","citation_count":69,"is_preprint":false},{"pmid":"34923175","id":"PMC_34923175","title":"Hepatic TM6SF2 Is Required for Lipidation of VLDL in a Pre-Golgi Compartment in Mice and Rats.","date":"2021","source":"Cellular and molecular gastroenterology and hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/34923175","citation_count":68,"is_preprint":false},{"pmid":"25566323","id":"PMC_25566323","title":"TM6SF2 and MAC30, new enzyme homologs in sterol metabolism and common metabolic disease.","date":"2014","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25566323","citation_count":51,"is_preprint":false},{"pmid":"32776921","id":"PMC_32776921","title":"Disruption of the ERLIN-TM6SF2-APOB complex destabilizes APOB and contributes to non-alcoholic fatty liver disease.","date":"2020","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/32776921","citation_count":51,"is_preprint":false},{"pmid":"25581573","id":"PMC_25581573","title":"TM6SF2 E167K variant is associated with severe steatosis in chronic hepatitis C, regardless of PNPLA3 polymorphism.","date":"2015","source":"Liver international : official journal of the International Association for the Study of the Liver","url":"https://pubmed.ncbi.nlm.nih.gov/25581573","citation_count":46,"is_preprint":false},{"pmid":"28449094","id":"PMC_28449094","title":"Hepatic Tm6sf2 overexpression affects cellular ApoB-trafficking, plasma lipid levels, hepatic steatosis and atherosclerosis.","date":"2017","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/28449094","citation_count":45,"is_preprint":false},{"pmid":"31752753","id":"PMC_31752753","title":"Association of TM6SF2 rs58542926 T/C gene polymorphism with hepatocellular carcinoma: a meta-analysis.","date":"2019","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/31752753","citation_count":42,"is_preprint":false},{"pmid":"28242789","id":"PMC_28242789","title":"TM6SF2 rs58542926 variant affects postprandial lipoprotein metabolism and glucose homeostasis in NAFLD.","date":"2017","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/28242789","citation_count":42,"is_preprint":false},{"pmid":"30875804","id":"PMC_30875804","title":"TM6SF2 and MBOAT7 Gene Variants in Liver Fibrosis and Cirrhosis.","date":"2019","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30875804","citation_count":33,"is_preprint":false},{"pmid":"30824369","id":"PMC_30824369","title":"Meta-analysis of the association between MBOAT7 rs641738, TM6SF2 rs58542926 and nonalcoholic fatty liver disease susceptibility.","date":"2019","source":"Clinics and research in hepatology and gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/30824369","citation_count":29,"is_preprint":false},{"pmid":"29232562","id":"PMC_29232562","title":"TM6SF2: A novel target for plasma lipid regulation.","date":"2017","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/29232562","citation_count":27,"is_preprint":false},{"pmid":"28434889","id":"PMC_28434889","title":"Depletion of TM6SF2 disturbs membrane lipid composition and dynamics in HuH7 hepatoma cells.","date":"2017","source":"Biochimica et biophysica acta. Molecular and cell biology of lipids","url":"https://pubmed.ncbi.nlm.nih.gov/28434889","citation_count":27,"is_preprint":false},{"pmid":"29574608","id":"PMC_29574608","title":"Fish intake interacts with TM6SF2 gene variant to affect NAFLD risk: results of a case-control study.","date":"2018","source":"European journal of nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/29574608","citation_count":27,"is_preprint":false},{"pmid":"32093693","id":"PMC_32093693","title":"Independent and joint correlation of PNPLA3 I148M and TM6SF2 E167K variants with the risk of coronary heart disease in patients with non-alcoholic fatty liver disease.","date":"2020","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/32093693","citation_count":22,"is_preprint":false},{"pmid":"27278285","id":"PMC_27278285","title":"Meta-analysis of the influence of TM6SF2 E167K variant on Plasma Concentration of Aminotransferases across different Populations and Diverse Liver Phenotypes.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27278285","citation_count":20,"is_preprint":false},{"pmid":"34692725","id":"PMC_34692725","title":"PNPLA3, TM6SF2, and MBOAT7 Influence on Nutraceutical Therapy Response for Non-alcoholic Fatty Liver Disease: A Randomized Controlled Trial.","date":"2021","source":"Frontiers in medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34692725","citation_count":20,"is_preprint":false},{"pmid":"31054977","id":"PMC_31054977","title":"Interaction of TM6SF2 E167K and PNPLA3 I148M variants in NAFLD in northeast China.","date":"2019","source":"Annals of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/31054977","citation_count":19,"is_preprint":false},{"pmid":"30727943","id":"PMC_30727943","title":"Association of TM6SF2 rs58542926 gene polymorphism with the risk of non-alcoholic fatty liver disease and colorectal adenoma in Chinese Han population.","date":"2019","source":"BMC biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30727943","citation_count":19,"is_preprint":false},{"pmid":"39054606","id":"PMC_39054606","title":"TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD.","date":"2024","source":"Clinical and molecular hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/39054606","citation_count":18,"is_preprint":false},{"pmid":"30271746","id":"PMC_30271746","title":"The Genetics of Clinical Liver Diseases: Insight into the TM6SF2 E167K Variant.","date":"2018","source":"Journal of clinical and translational hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/30271746","citation_count":16,"is_preprint":false},{"pmid":"34746691","id":"PMC_34746691","title":"Type 2 diabetes sex-specific effects associated with E167K coding variant in TM6SF2.","date":"2021","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/34746691","citation_count":16,"is_preprint":false},{"pmid":"39779889","id":"PMC_39779889","title":"Intestinal TM6SF2 protects against metabolic dysfunction-associated steatohepatitis through the gut-liver axis.","date":"2025","source":"Nature metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/39779889","citation_count":15,"is_preprint":false},{"pmid":"32568739","id":"PMC_32568739","title":"Association of the NCAN-TM6SF2-CILP2-PBX4-SUGP1-MAU2 SNPs and gene-gene and gene-environment interactions with serum lipid levels.","date":"2020","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/32568739","citation_count":15,"is_preprint":false},{"pmid":"34503201","id":"PMC_34503201","title":"Lipid Droplet-Associated Factors, PNPLA3, TM6SF2, and HSD17B Proteins in Hepatopancreatobiliary Cancer.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/34503201","citation_count":14,"is_preprint":false},{"pmid":"34590679","id":"PMC_34590679","title":"Meta-GWAS of PCSK9 levels detects two novel loci at APOB and TM6SF2.","date":"2022","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/34590679","citation_count":14,"is_preprint":false},{"pmid":"29761171","id":"PMC_29761171","title":"Coding variants in PNPLA3 and TM6SF2 are risk factors for hepatic steatosis and elevated serum alanine aminotransferases caused by a glucagon receptor antagonist.","date":"2018","source":"Hepatology communications","url":"https://pubmed.ncbi.nlm.nih.gov/29761171","citation_count":14,"is_preprint":false},{"pmid":"39667906","id":"PMC_39667906","title":"Hepatic TM6SF2 activates antitumour immunity to suppress metabolic dysfunction-associated steatotic liver disease-related hepatocellular carcinoma and boosts immunotherapy.","date":"2025","source":"Gut","url":"https://pubmed.ncbi.nlm.nih.gov/39667906","citation_count":13,"is_preprint":false},{"pmid":"30144428","id":"PMC_30144428","title":"TM6SF2 Promotes Lipidation and Secretion of Hepatitis C Virus in Infected Hepatocytes.","date":"2018","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/30144428","citation_count":13,"is_preprint":false},{"pmid":"35978872","id":"PMC_35978872","title":"Mechanism and therapeutic strategy of hepatic TM6SF2-deficient non-alcoholic fatty liver diseases via in vivo and in vitro experiments.","date":"2022","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/35978872","citation_count":13,"is_preprint":false},{"pmid":"38465912","id":"PMC_38465912","title":"Basic and translational evidence supporting the role of TM6SF2 in VLDL metabolism.","date":"2024","source":"Current opinion in lipidology","url":"https://pubmed.ncbi.nlm.nih.gov/38465912","citation_count":12,"is_preprint":false},{"pmid":"35057689","id":"PMC_35057689","title":"Research progress on the relationship between TM6SF2 rs58542926 polymorphism and non-alcoholic fatty liver disease.","date":"2022","source":"Expert review of gastroenterology & hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/35057689","citation_count":12,"is_preprint":false},{"pmid":"29088779","id":"PMC_29088779","title":"The additive effects of the TM6SF2 E167K and PNPLA3 I148M polymorphisms on lipid metabolism.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29088779","citation_count":12,"is_preprint":false},{"pmid":"26756786","id":"PMC_26756786","title":"Associations of TM6SF2 167K allele with liver enzymes and lipid profile in children: the PANIC Study.","date":"2016","source":"Pediatric research","url":"https://pubmed.ncbi.nlm.nih.gov/26756786","citation_count":11,"is_preprint":false},{"pmid":"28950858","id":"PMC_28950858","title":"Identification of deleterious rare variants in MTTP, PNPLA3, and TM6SF2 in Japanese males and association studies with NAFLD.","date":"2017","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/28950858","citation_count":10,"is_preprint":false},{"pmid":"36139452","id":"PMC_36139452","title":"Myeloid TM6SF2 Deficiency Inhibits Atherosclerosis.","date":"2022","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/36139452","citation_count":9,"is_preprint":false},{"pmid":"28407767","id":"PMC_28407767","title":"E167K polymorphism of TM6SF2 gene affects cell cycle of hepatocellular carcinoma cell HEPA 1-6.","date":"2017","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/28407767","citation_count":9,"is_preprint":false},{"pmid":"27784963","id":"PMC_27784963","title":"TM6SF2 E167K variant predicts severe liver fibrosis for human immunodeficiency/hepatitis C virus co-infected patients, and severe steatosis only for a non-3 hepatitis C virus genotype.","date":"2016","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/27784963","citation_count":9,"is_preprint":false},{"pmid":"33565643","id":"PMC_33565643","title":"Variants in PCSK7, PNPLA3 and TM6SF2 are risk factors for the development of cirrhosis in hereditary haemochromatosis.","date":"2021","source":"Alimentary pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/33565643","citation_count":8,"is_preprint":false},{"pmid":"30161167","id":"PMC_30161167","title":"PNPLA3 p.I148M and TM6SF2 p.E167K variants do not predispose to liver injury in cholestatic liver diseases: A prospective analysis of 178 patients with PSC.","date":"2018","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/30161167","citation_count":8,"is_preprint":false},{"pmid":"38776916","id":"PMC_38776916","title":"The common p.Ile291Val variant of ERLIN1 enhances TM6SF2 function and is associated with protection against MASLD.","date":"2024","source":"Med (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/38776916","citation_count":7,"is_preprint":false},{"pmid":"34575933","id":"PMC_34575933","title":"Perturbation of TM6SF2 Expression Alters Lipid Metabolism in a Human Liver Cell Line.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34575933","citation_count":6,"is_preprint":false},{"pmid":"30944816","id":"PMC_30944816","title":"TM6SF2 E167K Variant Overexpression Promotes Expression of Inflammatory Cytokines in the HCC Cell Line HEPA 1-6.","date":"2019","source":"Journal of clinical and translational hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/30944816","citation_count":6,"is_preprint":false},{"pmid":"40833996","id":"PMC_40833996","title":"Human-induced pluripotent stem cell-based hepatic modeling of lipid metabolism-associated TM6SF2-E167K variant.","date":"2024","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/40833996","citation_count":5,"is_preprint":false},{"pmid":"36028802","id":"PMC_36028802","title":"PNPLA3 and TM6SF2 genetic variants and hepatic fibrosis and cirrhosis in Pakistani chronic hepatitis C patients: a genetic association study.","date":"2022","source":"BMC gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/36028802","citation_count":5,"is_preprint":false},{"pmid":"37271250","id":"PMC_37271250","title":"TM6SF2 reduces lipid accumulation in vascular smooth muscle cells by inhibiting LOX-1 and CD36 expression.","date":"2023","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/37271250","citation_count":5,"is_preprint":false},{"pmid":"30616151","id":"PMC_30616151","title":"Relationship between N,N-dimethylformamide exposure, PNPLA3, GCKR, COL13A1 and TM6SF2 genes, and liver injury.","date":"2019","source":"Ecotoxicology and environmental safety","url":"https://pubmed.ncbi.nlm.nih.gov/30616151","citation_count":5,"is_preprint":false},{"pmid":"36685261","id":"PMC_36685261","title":"The TM6SF2 variant as a risk factor for hepatocellular carcinoma development in chronic liver disease patients.","date":"2022","source":"Clinical and experimental hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/36685261","citation_count":5,"is_preprint":false},{"pmid":"35143946","id":"PMC_35143946","title":"Evaluation of the association of a variant in PNPLA3 and TM6SF2 with fibrosis progression in patients with chronic hepatitis C infection after eradication: A retrospective study.","date":"2022","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/35143946","citation_count":5,"is_preprint":false},{"pmid":"37400794","id":"PMC_37400794","title":"Metabolic disorders induced by PNPLA3 and TM6SF2 gene variants affect chronic kidney disease in patients infected with non-genotype 3 hepatitis C virus.","date":"2023","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/37400794","citation_count":4,"is_preprint":false},{"pmid":"30572387","id":"PMC_30572387","title":"[Effects of PNPLA3, TM6SF2 gene polymorphisms and its interactions with smoking and alcohol drinking on hepatitis B virus-associated hepatocellular carcinoma].","date":"2018","source":"Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi","url":"https://pubmed.ncbi.nlm.nih.gov/30572387","citation_count":4,"is_preprint":false},{"pmid":"37425717","id":"PMC_37425717","title":"TM6SF2 Determines Both the Degree of Lipidation and the Number of VLDL Particles Secreted by the Liver.","date":"2023","source":"medRxiv : the preprint server for health sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37425717","citation_count":3,"is_preprint":false},{"pmid":"41492318","id":"PMC_41492318","title":"PNPLA3 and TM6SF2 exacerbate the impact of alcohol and metabolic dysfunction on liver fibrosis.","date":"2025","source":"JHEP reports : innovation in hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/41492318","citation_count":3,"is_preprint":false},{"pmid":"37495452","id":"PMC_37495452","title":"Effects of TM6SF2 rs58542926 polymorphism on hepatocellular lipids and insulin resistance in early type 2 diabetes.","date":"2023","source":"Nutrition, metabolism, and cardiovascular diseases : NMCD","url":"https://pubmed.ncbi.nlm.nih.gov/37495452","citation_count":3,"is_preprint":false},{"pmid":"39215018","id":"PMC_39215018","title":"G-quadruplex forming regions in GCK and TM6SF2 are targets for differential DNA methylation in metabolic disease and hepatocellular carcinoma patients.","date":"2024","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/39215018","citation_count":3,"is_preprint":false},{"pmid":"34794021","id":"PMC_34794021","title":"Relationships among N,N-dimethylformamide exposure, CYP2E1 and TM6SF2 genes, and non-alcoholic fatty liver disease.","date":"2021","source":"Ecotoxicology and environmental safety","url":"https://pubmed.ncbi.nlm.nih.gov/34794021","citation_count":3,"is_preprint":false},{"pmid":"33685085","id":"PMC_33685085","title":"[Correlation between PNPLA3 rs738409 and TM6SF2 rs58542926 gene polymorphism and primary liver cancer in the Han Population of China's Northeast region].","date":"2021","source":"Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/33685085","citation_count":3,"is_preprint":false},{"pmid":"36904112","id":"PMC_36904112","title":"TM6SF2-rs58542926 Genetic Variant Modifies the Protective Effect of a \"Prudent\" Dietary Pattern on Serum Triglyceride Levels.","date":"2023","source":"Nutrients","url":"https://pubmed.ncbi.nlm.nih.gov/36904112","citation_count":3,"is_preprint":false},{"pmid":"39687601","id":"PMC_39687601","title":"Deep metabolic phenotyping of humans with protein-altering variants in TM6SF2 using a genome-first approach.","date":"2024","source":"JHEP reports : innovation in hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/39687601","citation_count":2,"is_preprint":false},{"pmid":"40065199","id":"PMC_40065199","title":"Association between single nucleotide polymorphisms in PNPLA3, TM6SF2 and MBOAT7 genes and markers of cancer aggressiveness in a Sri Lankan NASH-related HCC cohort.","date":"2025","source":"BMC gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/40065199","citation_count":2,"is_preprint":false},{"pmid":"40806538","id":"PMC_40806538","title":"Contribution of PNPLA3, GCKR, MBOAT7, NCAN, and TM6SF2 Genetic Variants to Hepatocellular Carcinoma Development in Mexican Patients.","date":"2025","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/40806538","citation_count":1,"is_preprint":false},{"pmid":"37589914","id":"PMC_37589914","title":"A study of genetic variants, genetic risk score and DNA methylation of PNPLA3 and TM6SF2 in alcohol liver cirrhosis.","date":"2023","source":"Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/37589914","citation_count":1,"is_preprint":false},{"pmid":"38187603","id":"PMC_38187603","title":"Human Induced Pluripotent Stem Cell based Hepatic-Modeling of Lipid metabolism associated TM6SF2 E167K variant.","date":"2023","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/38187603","citation_count":1,"is_preprint":false},{"pmid":"38408366","id":"PMC_38408366","title":"Inhibition of Cellular Factor TM6SF2 Suppresses Secretion Pathways of Hepatitis B, Hepatitis C, and Hepatitis D Viruses.","date":"2024","source":"The Journal of infectious diseases","url":"https://pubmed.ncbi.nlm.nih.gov/38408366","citation_count":1,"is_preprint":false},{"pmid":"38163971","id":"PMC_38163971","title":"GDF-10 Induces an Inhibitory Effect on Epithelial-Mesenchymal Transition of Laryngeal Cancer via LPR4.","date":"2023","source":"Current pharmaceutical design","url":"https://pubmed.ncbi.nlm.nih.gov/38163971","citation_count":0,"is_preprint":false},{"pmid":"40474882","id":"PMC_40474882","title":"Intestinal Depletion of TM6SF2 Exacerbates High-fat Diet-induced Metabolic Dysfunction-associated Steatotic Liver Disease through the Gut-liver Axis.","date":"2025","source":"Journal of clinical and translational hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/40474882","citation_count":0,"is_preprint":false},{"pmid":"41244049","id":"PMC_41244049","title":"PNPLA3-Ile148Met and TM6SF2-Glu167Lys increase susceptibility to metabolic dysfunction-associated steatotic liver disease in children.","date":"2025","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/41244049","citation_count":0,"is_preprint":false},{"pmid":"40504324","id":"PMC_40504324","title":"Impact of differential detection of TM6SF2 rs58542926 mutation in circulating tumor DNA versus peripheral blood cells on hepatocellular carcinoma patients.","date":"2025","source":"Discover oncology","url":"https://pubmed.ncbi.nlm.nih.gov/40504324","citation_count":0,"is_preprint":false},{"pmid":"42023869","id":"PMC_42023869","title":"Analysis of PNPLA3, TM6SF2 and GCKR gene polymorphisms in patients with metabolic dysfunction-associated steatohepatitis treated with probiotics ‒ An exploratory study.","date":"2026","source":"Nutricion hospitalaria","url":"https://pubmed.ncbi.nlm.nih.gov/42023869","citation_count":0,"is_preprint":false},{"pmid":"41384813","id":"PMC_41384813","title":"Genetic risk of alcohol-related liver cirrhosis: Associations of PNPLA3, TM6SF2, and a two-variant polygenic risk score.","date":"2025","source":"Biomolecules & biomedicine","url":"https://pubmed.ncbi.nlm.nih.gov/41384813","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.11.18.25338158","title":"Modeling Familial MASH by iPSC-Hepatocytes","date":"2025-11-22","source":"bioRxiv","url":"https://doi.org/10.1101/2025.11.18.25338158","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.01.14.25320567","title":"Discovering Novel Genome Mutations Associated with Liver and Pancreas Disorders: Insights from a Radiogenomics Study","date":"2025-01-15","source":"bioRxiv","url":"https://doi.org/10.1101/2025.01.14.25320567","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.11.05.24316758","title":"Potential causal links between genetic variants in<i>SAMM50</i>,<i>SUGP1</i>,<i>MAU2</i>, and<i>GATAD2A</i>and liver fat in individuals with normal weight","date":"2024-11-05","source":"bioRxiv","url":"https://doi.org/10.1101/2024.11.05.24316758","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":54546,"output_tokens":6155,"usd":0.127981,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":15021,"output_tokens":4426,"usd":0.092878,"stage2_stop_reason":"end_turn"},"total_usd":0.220859,"stage1_batch_id":"msgbatch_017qqVz33Ga63SCDwzb35XPb","stage2_batch_id":"msgbatch_01Scr2Ei9x4HJMiRGxwrmvLK","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2014,\n      \"finding\": \"TM6SF2 is localized in the endoplasmic reticulum and ER-Golgi intermediate compartment of human liver cells, and siRNA knockdown reduces secretion of triglyceride-rich lipoproteins while increasing intracellular triglyceride content and lipid droplet content; overexpression reduces hepatocyte steatosis.\",\n      \"method\": \"Confocal microscopy subcellular localization, siRNA knockdown, overexpression in Huh7 and HepG2 cells with lipid/TG secretion assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal loss-of-function and gain-of-function experiments with multiple orthogonal methods (confocal localization, siRNA, overexpression, TG secretion assay) in human hepatoma cells\",\n      \"pmids\": [\"24927523\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"AAV-mediated shRNA knockdown of Tm6sf2 in mice increased liver triglyceride content threefold and decreased VLDL secretion by 50%, establishing TM6SF2 as required for normal VLDL secretion in vivo; the E167K variant produces ~50% less protein when expressed in cultured hepatocytes.\",\n      \"method\": \"AAV-shRNA knockdown in mice, VLDL secretion assays, recombinant protein expression in hepatocytes\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo mouse knockdown with quantitative VLDL secretion readout replicated across multiple independent lines of evidence\",\n      \"pmids\": [\"24531328\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Genetic inactivation of Tm6sf2 in mice causes hepatic steatosis, hypocholesterolemia, and reduced VLDL-TG secretion (3-fold decrease in rate) without reduction in hepatic apoB secretion; TM6SF2 localizes to ER and Golgi; excess neutral lipids accumulate in lipid droplets distinct from TM6SF2 localization, indicating TM6SF2 is required to mobilize neutral lipids for VLDL assembly but not for apoB-containing lipoprotein secretion per se.\",\n      \"method\": \"Germline Tm6sf2 knockout mice, immunocytochemistry, cell fractionation, VLDL-TG secretion rate measurement, dietary lipid absorption assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — full knockout mouse model with multiple orthogonal quantitative methods separating TG secretion from apoB secretion\",\n      \"pmids\": [\"27013658\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Liver-specific Tm6sf2 knockout mice exhibit spontaneous hepatic steatosis with reduced VLDL-TG secretion, small underlipidated VLDL particles, and unchanged or increased apolipoprotein B; AAV8-mediated rescue with either wild-type or E167K-mutant Tm6sf2 reduced hepatic steatosis and improved VLDL secretion; on fibrogenic diets, Tm6sf2 LKO mice show increased steatosis, fibrosis, and accelerated HCC.\",\n      \"method\": \"Liver-specific conditional knockout mice (two independent lines), AAV8 rescue, targeted lipidomics, in vivo VLDL secretion, dietary challenge models, HCC induction models\",\n      \"journal\": \"Hepatology (Baltimore, Md.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — two independent knockout lines, AAV rescue, lipidomics, multiple disease models in a single rigorous study\",\n      \"pmids\": [\"33638902\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TM6SF2 resides predominantly in smooth endoplasmic reticulum and ER-Golgi intermediate compartments (not Golgi). In Tm6sf2-knockout rats, VLDL lipid content (TG and cholesterol) from perfused livers was reduced by ~53–62%. Immunoprecipitation identified apolipoprotein B-48 and ACSL5 (acyl-CoA synthetase long chain family member 5) as TM6SF2-interacting proteins, placing TM6SF2 function at the smooth ER for bulk lipidation of apoB-containing lipoproteins.\",\n      \"method\": \"Gene-edited Tm6sf2-knockout rats, cell fractionation, perfused liver VLDL lipid quantification by mass spectrometry, co-immunoprecipitation from liver and enterocytes\",\n      \"journal\": \"Cellular and molecular gastroenterology and hepatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — orthogonal methods including cell fractionation, perfused liver VLDL quantification, and co-IP identifying specific binding partners\",\n      \"pmids\": [\"34923175\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"TM6SF2 forms a complex with ERLIN1, ERLIN2, and APOB. ERLINs and TM6SF2 mutually bind and stabilize each other. TM6SF2 binds and stabilizes APOB via two luminal loops; the E167K mutation reduces TM6SF2 protein expression, destabilizing APOB and leading to hepatic lipid accumulation and reduced serum lipid levels. Knockout of Tm6sf2 or knockdown of Erlins in mice decreases hepatic APOB protein level.\",\n      \"method\": \"Tandem affinity purification combined with mass spectrometry, co-IP, mutagenesis (luminal loop mapping), mouse Tm6sf2 KO and Erlin knockdown with hepatic lipid and APOB measurements\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — TAP-MS for complex identification, co-IP validation, domain mutagenesis, and in vivo mouse KO confirmation in a single study\",\n      \"pmids\": [\"32776921\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Hepatic overexpression of Tm6sf2 in mice (via AAV) reduces plasma lipid levels and VLDL-TG secretion and increases hepatosteatosis, mirroring loss-of-function phenotype. In cultured human hepatocytes, TM6SF2 overexpression reduces apoB secretion and causes its accumulation in the ER, suggesting impaired ER-to-Golgi trafficking of pre-VLDL particles. Both E167K (rs58542926) and L156P (rs187429064) variants reduce TM6SF2 protein by increasing protein turnover rate.\",\n      \"method\": \"AAV-mediated hepatic overexpression in mice, cultured human hepatocyte apoB secretion assay, protein turnover experiments comparing variant vs. wild-type TM6SF2\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo overexpression mouse model, in vitro human hepatocyte mechanistic assay, and biochemical protein stability analysis in one study\",\n      \"pmids\": [\"28449094\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"TM6SF2 knockdown in HuH7 cells results in intracellular accumulation of TAGs and cholesterol esters with depletion of polyunsaturated fatty acid species (especially arachidonic acid) in phosphatidylcholines, increased lipid synthesis and turnover, secretion of smaller lipoprotein-like particles, increased lysosome/endosome structures, and reduced mitochondrial palmitate oxidation capacity.\",\n      \"method\": \"Stable siRNA knockdown in HuH7 cells, lipidomics (lipid class and species composition), mitochondrial fatty acid oxidation assay, electron microscopy\",\n      \"journal\": \"Biochimica et biophysica acta. Molecular and cell biology of lipids\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods in a single lab with stable knockdown and quantitative lipid/functional readouts\",\n      \"pmids\": [\"28434889\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"In human liver biopsies and TM6SF2 knockdown HuH-7 cells, TM6SF2 E167K variant carriers show decreased polyunsaturated fatty acid (PUFA) incorporation into triglycerides and phosphatidylcholines (PC), with PC deficiency and increased intrahepatic TG, demonstrating that TM6SF2 is required for hepatic lipid synthesis from PUFAs.\",\n      \"method\": \"Liver biopsies with genotyping and lipidomics, siRNA knockdown in HuH-7 cells with fatty acid incorporation assays, gene co-expression analysis\",\n      \"journal\": \"Journal of hepatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — human liver biopsy lipidomics combined with cell-based PUFA incorporation assays, replicated across in vivo and in vitro contexts\",\n      \"pmids\": [\"28235613\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TM6SF2 silencing in HepG2 cells (via CRISPR/Cas9) alters lipid composition, induces accumulation of microvesicular lipid droplets, strongly affects ER and mitochondrial ultrastructure, increases ER and oxidative stress, increases mitochondrial number (imbalanced mitochondrial dynamics), and impairs mitochondrial activity with shift toward anaerobic glycolysis. Re-overexpression of TM6SF2 reverses these metabolic and tumorigenic features.\",\n      \"method\": \"CRISPR/Cas9 knockout in HepG2 cells, electron microscopy (ultrastructure), mitochondrial function assays, metabolic reprogramming assays, rescue overexpression\",\n      \"journal\": \"Cellular and molecular gastroenterology and hepatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — CRISPR KO with rescue, multiple orthogonal functional readouts in a single lab\",\n      \"pmids\": [\"34823063\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"TM6SF2 knockdown in hepatocytes reduces HCV infectious viral particle secretion and RNA levels without affecting HCV genome replication, translation, or assembly; TM6SF2 overexpression increases secretion of infectious lipoviroparticles in lower-density fractions. HCV infection upregulates TM6SF2 expression via SREBF2, and TM6SF2 is required for maturation, lipidation, and secretion of HCV lipoviroparticles.\",\n      \"method\": \"siRNA knockdown and overexpression in HCV-infected hepatocytes, iodixanol gradient density fractionation of LVPs, viral RNA/protein quantification, liver biopsies from HCV patients and humanized mice\",\n      \"journal\": \"Gastroenterology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal KD/OE experiments with quantitative viral secretion readout, corroborated by humanized mouse and human biopsy data\",\n      \"pmids\": [\"30144428\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"TM6SF2 knockdown in human hepatocytes reduces secretion of infectious HBV subviral particles, HCV virions, and HDV virions; carriers of the TM6SF2 rs58542926 CT/TT polymorphism have lower HBV subviral particle concentrations in blood, demonstrating TM6SF2 as a host factor required for secretion of all three hepatitis viruses via the ER-Golgi pathway.\",\n      \"method\": \"siRNA knockdown in virus cell culture models for HBV, HCV, HDV; clinical cohort correlation of TM6SF2 polymorphism with HBV subviral particle levels\",\n      \"journal\": \"The Journal of infectious diseases\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-based KD with multiple virus systems, supported by clinical cohort data, single lab\",\n      \"pmids\": [\"38408366\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TM6SF2 interacts with IRE1α (inositol-requiring enzyme 1α), a primary ER stress sensor; male E167K knock-in mice exhibit impaired IRE1α signaling in the liver and glucose intolerance, while female KI mice do not, indicating sex-specific TM6SF2-IRE1α interaction effects on glucose metabolism.\",\n      \"method\": \"E167K knock-in mouse model, glucose tolerance testing, co-immunoprecipitation of TM6SF2 with IRE1α, hepatic IRE1α signaling assays\",\n      \"journal\": \"iScience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KI mouse model with co-IP interaction and functional metabolic readout, single lab\",\n      \"pmids\": [\"34746691\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Intestinal epithelial cell-specific Tm6sf2 knockout mice develop MASH; mechanistically, Tm6sf2-deficient intestinal cells secrete more free fatty acids by interacting with fatty acid-binding protein 5 (FABP5), causing intestinal barrier dysfunction, microbial dysbiosis, and elevation of lysophosphatidic acid (LPA). LPA translocates from gut to liver contributing to hepatic lipid accumulation and inflammation. Pharmacological inhibition of the LPA receptor suppresses MASH.\",\n      \"method\": \"Intestinal epithelial-specific Tm6sf2 KO mice, germ-free fecal transplant experiments, co-housing with wild-type mice, LPA measurement, LPA receptor inhibitor treatment, co-immunoprecipitation with FABP5\",\n      \"journal\": \"Nature metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — intestine-specific KO with germ-free transplant and co-housing mechanistic controls, molecular interaction identified, pharmacological rescue, multiple orthogonal methods\",\n      \"pmids\": [\"39779889\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Hepatic TM6SF2 directly binds IKKβ and inhibits NF-κB signaling, reducing IL-6 secretion and thereby maintaining cytotoxic CD8+ T cell activity; hepatocyte-specific Tm6sf2 knockout reduces IFN-γ+ CD8+ T cells in tumors and promotes MASLD-HCC, while IL-6 neutralization abolishes the tumor-promoting effect of Tm6sf2 knockout.\",\n      \"method\": \"Hepatocyte-specific Tm6sf2 KO mice, orthotopic MASLD-HCC models, co-immunoprecipitation of TM6SF2 with IKKβ, NF-κB signaling assays, CD8+ T cell depletion, IL-6 neutralization, adenoviral TM6SF2 overexpression\",\n      \"journal\": \"Gut\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — hepatocyte-specific KO with co-IP molecular interaction, NF-κB pathway assays, immune cell depletion, cytokine neutralization, and viral rescue across multiple models\",\n      \"pmids\": [\"39667906\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"TM6SF2 deficiency in macrophages (myeloid-specific KO on ApoE-/- background) inhibits atherosclerosis and decreases foam cell formation without changing plasma lipids. Silencing TM6SF2 in THP-1 macrophages reduces inflammatory responses, ER stress, and cholesterol uptake; TM6SF2 is upregulated by oxLDL in macrophages; overexpression shows opposite effects.\",\n      \"method\": \"Myeloid-specific Tm6sf2 KO mice on ApoE-/- background, Western diet atherosclerosis model, RNA-seq of BMDMs, siRNA knockdown and overexpression in THP-1 macrophages with cholesterol uptake and ER stress assays\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-type-specific KO mouse model with reciprocal KD/OE in macrophages, multiple functional readouts, single lab\",\n      \"pmids\": [\"36139452\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TM6SF2 reduces lipid accumulation in vascular smooth muscle cells (VSMCs) exposed to oxLDL by downregulating expression of the scavenger receptors LOX-1 and CD36.\",\n      \"method\": \"siRNA knockdown and overexpression of TM6SF2 in HAVSMCs, lipid accumulation assay, LOX-1 and CD36 expression measurement\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, single cell type, KD/OE with gene expression readout but limited mechanistic depth\",\n      \"pmids\": [\"37271250\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"The TM6SF2 E167K variant increases interaction between TM6SF2 and PNPLA3, impairing PNPLA3-mediated transfer of polyunsaturated fatty acids (PUFAs) from TG to PC; this results in decreased polyunsaturated PC and increased polyunsaturated TG in liver. Dietary supplementation of PC containing C18:3 attenuates E167K-induced hepatic steatosis in HFD-fed mice.\",\n      \"method\": \"Tm6sf2 E167K knock-in mice on HFD, hepatic lipidomics, TLC for newly synthesized TG/PC, co-immunoprecipitation of TM6SF2 with PNPLA3 (comparing WT vs. E167K), dietary PC C18:3 supplementation\",\n      \"journal\": \"Clinical and molecular hepatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KI mouse model with co-IP interaction mapping, lipidomics, and dietary rescue, single lab\",\n      \"pmids\": [\"39054606\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Computational sequence analysis identified a novel conserved domain (EXPERA domain) shared between TM6SF2, MAC30/TMEM97, and EBP (D8/D7 sterol isomerase) families, predicting catalytic activity as a sterol isomerase for TM6SF2 based on evolutionary conservation of predicted active-site residues.\",\n      \"method\": \"Computational protein sequence analysis, evolutionary conservation analysis, domain prediction\",\n      \"journal\": \"Frontiers in genetics\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 4 / Weak — computational prediction only, no experimental validation of enzymatic activity in this study\",\n      \"pmids\": [\"25566323\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"In human hepatic 3D spheroids from primary hepatocytes, the TM6SF2 E167K variant induces increased hepatocyte fat content by reducing APOB particle secretion, confirmed across five donors with inter-donor variability reflected in the model.\",\n      \"method\": \"3D spheroid model from primary human hepatocytes with TM6SF2 E167K variant carriers vs. wild-type, APOB secretion measurement, lipid content assay\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — primary human hepatocyte 3D model with multiple donors, functional APOB secretion readout, single lab\",\n      \"pmids\": [\"31406127\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"TM6SF2 deficiency (knockdown) in hepatocytes enhances fatty acid uptake and synthesis and impairs fatty acid oxidation, leading to intracellular lipid deposition. Treatment with the acetyl-CoA carboxylase inhibitor MK-4074 reverses NAFLD phenotypes caused by TM6SF2 deficiency, placing TM6SF2 upstream of de novo lipogenesis regulation.\",\n      \"method\": \"siRNA knockdown and overexpression in hepatocytes, RNA-seq, in vivo NAFLD mouse model, MK-4074 pharmacological rescue\",\n      \"journal\": \"World journal of gastroenterology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell KD/OE with gene expression analysis and pharmacological rescue, single lab\",\n      \"pmids\": [\"35978872\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"The protective effect of the ERLIN1 p.Ile291Val variant against MASLD is not apparent in individuals carrying the TM6SF2 p.Glu167Lys variant, suggesting functional epistasis: ERLIN1 p.Ile291Val may act as a gain-of-function variant that enhances TM6SF2 function, consistent with the known ERLIN1-TM6SF2-APOB complex.\",\n      \"method\": \"Genome-first approach in UK Biobank, Penn Medicine Biobank, and All of Us cohorts; predicted loss-of-function ERLIN1 variant analysis showing opposite lipid effects; epistasis analysis with TM6SF2 E167K\",\n      \"journal\": \"Med (New York, N.Y.)\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — human genetic epistasis inference from biobank data without direct biochemical validation of ERLIN1-TM6SF2 functional interaction\",\n      \"pmids\": [\"38776916\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TM6SF2 is a polytopic ER-resident membrane protein (with EXPERA domain) that localizes to the smooth ER and ER-Golgi intermediate compartment where it forms a complex with ERLIN1/2 and stabilizes APOB, promotes bulk lipidation of nascent apoB-containing VLDL particles (required for TG loading but dispensable for apoB secretion per se), facilitates PUFA incorporation into phosphatidylcholines, enables secretion of hepatitis B/C/D virions via the ER-Golgi pathway, suppresses NF-κB/IKKβ-IL-6 signaling to maintain hepatic antitumor CD8+ T cell immunity, and in intestinal cells interacts with FABP5 to regulate fatty acid secretion and gut-liver LPA signaling; the disease-associated E167K variant reduces protein stability/expression, impairs VLDL lipidation and APOB stabilization, increases interaction with PNPLA3 to block PUFA transfer from TG to PC, and activates ER stress—collectively causing hepatic steatosis, fibrosis, and increased HCC risk.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"TM6SF2 is an endoplasmic reticulum and ER-Golgi intermediate compartment membrane protein that governs hepatic lipid mobilization for the assembly and secretion of triglyceride-rich VLDL particles [#0, #2]. Loss of TM6SF2 in cells, mice, and rats reduces VLDL-TG secretion and causes intracellular triglyceride and lipid-droplet accumulation, yet leaves apoB secretion intact, establishing that TM6SF2 acts to lipidate nascent apoB-containing particles rather than to drive their secretion per se [#1, #2, #3]. Mechanistically, TM6SF2 localizes to the smooth ER where it binds apolipoprotein B-48 and ACSL5 to support bulk lipidation [#4], and it assembles into a complex with ERLIN1/ERLIN2 in which TM6SF2 and the ERLINs mutually stabilize one another and TM6SF2 binds and stabilizes APOB through two luminal loops [#5]. TM6SF2 also directs polyunsaturated fatty acid incorporation into phosphatidylcholines and triglycerides, a function required for normal hepatic lipid synthesis [#7, #8]. Beyond lipoprotein biology, TM6SF2 is a host factor required for ER-Golgi-dependent secretion of hepatitis B, C, and D viral particles [#10, #11], and in hepatocytes it binds IKKβ to suppress NF-κB/IL-6 signaling and sustain antitumor CD8+ T cell immunity, restraining MASLD-driven HCC [#14]. In intestinal epithelium TM6SF2 interacts with FABP5 to limit free fatty acid secretion, and its loss drives a gut-liver axis of dysbiosis and lysophosphatidic acid signaling that promotes MASH [#13]. The common E167K variant destabilizes TM6SF2 by accelerating its turnover, reducing protein levels, destabilizing APOB, and impairing VLDL lipidation [#5, #6, #19]; E167K additionally increases TM6SF2 interaction with PNPLA3 to block PUFA transfer from triglyceride to phosphatidylcholine, collectively causing steatosis, fibrosis, and elevated HCC risk [#3, #17].\",\n  \"teleology\": [\n    {\n      \"year\": 2014,\n      \"claim\": \"Established the core question of TM6SF2 function by showing it is an ER/ERGIC protein whose loss blocks triglyceride-rich lipoprotein secretion and causes hepatocellular lipid retention.\",\n      \"evidence\": \"Confocal localization with reciprocal siRNA knockdown and overexpression in Huh7/HepG2 cells; AAV-shRNA knockdown in mice with VLDL secretion assays\",\n      \"pmids\": [\"24927523\", \"24531328\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve whether the defect was in lipid loading or in particle secretion machinery\", \"Molecular partners and biochemical activity unidentified\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Resolved the step at which TM6SF2 acts by showing germline knockout reduces VLDL-TG secretion without reducing apoB secretion, separating lipidation from lipoprotein secretion.\",\n      \"evidence\": \"Germline Tm6sf2 knockout mice with VLDL-TG secretion rate measurement, fractionation, and lipid absorption assays\",\n      \"pmids\": [\"27013658\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No binding partners or enzymatic activity defined\", \"Mechanism of neutral lipid mobilization to nascent particles unknown\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Defined the lipid-species consequences of TM6SF2 loss, linking it to PUFA incorporation into phosphatidylcholines and triglycerides and to broader metabolic remodeling.\",\n      \"evidence\": \"Stable siRNA knockdown in HuH7 cells with lipidomics, mitochondrial oxidation and EM; human liver biopsy lipidomics with PUFA incorporation assays; AAV overexpression in mice and hepatocyte protein turnover assays\",\n      \"pmids\": [\"28434889\", \"28235613\", \"28449094\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct enzyme catalyzing PUFA transfer not identified at this stage\", \"Mechanistic basis for variant protein instability not fully resolved\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identified the molecular complex underlying TM6SF2 function by showing it binds and is mutually stabilized by ERLIN1/2 and stabilizes APOB via luminal loops, explaining how E167K causes APOB destabilization.\",\n      \"evidence\": \"Tandem affinity purification-mass spectrometry, co-IP, luminal-loop mutagenesis, and mouse KO/Erlin knockdown with hepatic APOB measurement\",\n      \"pmids\": [\"32776921\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry and structure of the TM6SF2-ERLIN-APOB complex not determined\", \"How the complex couples to lipid loading mechanistically unresolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Mapped TM6SF2 to the smooth ER and identified apoB-48 and ACSL5 as interacting partners, and confirmed in liver-specific KO that TM6SF2 produces underlipidated VLDL and drives steatosis, fibrosis, and HCC.\",\n      \"evidence\": \"Tm6sf2-knockout rats with perfused-liver VLDL lipid quantification and co-IP; liver-specific conditional KO mice with AAV8 rescue, lipidomics, and disease models; CRISPR KO in HepG2 with ultrastructure and mitochondrial assays\",\n      \"pmids\": [\"34923175\", \"33638902\", \"34823063\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional role of ACSL5 interaction in lipidation not dissected\", \"Causal chain from steatosis to fibrosis/HCC not fully mechanistic\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Extended TM6SF2 function to viral pathogenesis by showing it is required for maturation, lipidation, and secretion of HCV lipoviroparticles without affecting genome replication.\",\n      \"evidence\": \"siRNA knockdown/overexpression in HCV-infected hepatocytes with density gradient fractionation, plus humanized mouse and patient biopsy data\",\n      \"pmids\": [\"30144428\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether HCV co-opts the same ERLIN/APOB machinery untested\", \"Direct interaction with viral components not shown\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Generalized TM6SF2 as a pan-hepatitis host secretion factor for HBV, HCV, and HDV virions via the ER-Golgi pathway, with the E167K-associated genotype lowering circulating HBV subviral particles.\",\n      \"evidence\": \"siRNA knockdown across HBV/HCV/HDV cell culture models with clinical cohort polymorphism correlation\",\n      \"pmids\": [\"38408366\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab cell-based knockdown without reciprocal validation across systems\", \"Mechanism of shared secretion route not biochemically defined\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Connected TM6SF2 to ER stress sensing by demonstrating interaction with IRE1\\u03b1 and sex-specific effects of E167K on hepatic IRE1\\u03b1 signaling and glucose tolerance.\",\n      \"evidence\": \"E167K knock-in mice with glucose tolerance testing, co-IP of TM6SF2 with IRE1\\u03b1, and hepatic IRE1\\u03b1 signaling assays\",\n      \"pmids\": [\"34746691\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Basis of sex-specificity unexplained\", \"Single Co-IP for the IRE1\\u03b1 interaction without reciprocal/structural validation\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Revealed cell-type-specific roles of TM6SF2 beyond hepatocytes, in macrophage foam-cell formation, atherosclerosis, ER stress, and de novo lipogenesis regulation.\",\n      \"evidence\": \"Myeloid-specific Tm6sf2 KO on ApoE-/- background with atherosclerosis model and macrophage KD/OE; hepatocyte KD/OE with RNA-seq and ACC inhibitor MK-4074 rescue\",\n      \"pmids\": [\"36139452\", \"35978872\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular mechanism in macrophages not resolved to direct partners\", \"Single-lab studies with gene-expression readouts\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Defined a molecular mechanism for the E167K variant beyond protein instability by showing it increases TM6SF2-PNPLA3 interaction to block PUFA transfer from TG to PC, with dietary PC rescue.\",\n      \"evidence\": \"Tm6sf2 E167K knock-in mice on HFD with hepatic lipidomics, TLC, co-IP comparing WT vs E167K, and dietary PC C18:3 supplementation\",\n      \"pmids\": [\"39054606\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct enzymatic role of TM6SF2 in PUFA transfer versus modulation of PNPLA3 not separated\", \"Single-lab co-IP interaction mapping\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Identified non-cell-autonomous gut-liver and immune mechanisms: intestinal TM6SF2 limits FFA secretion via FABP5 to control an LPA gut-liver axis, while hepatic TM6SF2 binds IKK\\u03b2 to suppress NF-\\u03baB/IL-6 and preserve antitumor CD8+ T cell immunity.\",\n      \"evidence\": \"Intestinal-specific KO with germ-free transplant, co-housing, LPA receptor inhibitor, and FABP5 co-IP; hepatocyte-specific KO with orthotopic HCC models, IKK\\u03b2 co-IP, CD8+ T cell depletion, IL-6 neutralization, and viral rescue\",\n      \"pmids\": [\"39779889\", \"39667906\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How a lipidation protein engages IKK\\u03b2 and FABP5 mechanistically unresolved\", \"Interplay between metabolic and immune functions of TM6SF2 not integrated\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The intrinsic biochemical activity of TM6SF2 — whether it possesses the predicted EXPERA/sterol-isomerase catalytic function or acts purely as a scaffold for lipid loading — remains undefined.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"EXPERA-domain catalytic activity predicted computationally but never experimentally demonstrated\", \"No structure of TM6SF2 or its complexes\", \"Mechanistic coupling of partner binding to bulk lipidation unresolved\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [7, 8, 17]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [4, 5]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [0, 2, 4]},\n      {\"term_id\": \"GO:0005793\", \"supporting_discovery_ids\": [0, 4]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [2, 3, 7, 8]},\n      {\"term_id\": \"R-HSA-5653656\", \"supporting_discovery_ids\": [0, 1, 10]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [3, 13, 14]}\n    ],\n    \"complexes\": [\"TM6SF2-ERLIN1/ERLIN2-APOB complex\"],\n    \"partners\": [\"APOB\", \"ERLIN1\", \"ERLIN2\", \"ACSL5\", \"IRE1A\", \"PNPLA3\", \"FABP5\", \"IKBKB\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}